Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma

Jayashree Kalpathy-Cramer, Vyshak Chandra, Xiao da, Yangming Ou, Kyrre E. Emblem, Alona Muzikansky, Xuezhu Cai, Linda Douw, John G. Evans, Jorg Dietrich, Andrew S. Chi, Patrick Y. Wen, Stephen Stufflebeam, Bruce Rosen, Dan G. Duda, Rakesh K. Jain, Tracy T. Batchelor, Elizabeth R. Gerstner

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Targeting tumor angiogenesis is a potential therapeutic strategy for glioblastoma because of its high vascularization. Tivozanib is an oral pan-VEGF receptor tyrosine kinase inhibitor that hits a central pathway in glioblastoma angiogenesis. We conducted a phase II study to test the effectiveness of tivozanib in patients with recurrent glioblastoma. Ten adult patients were enrolled and treated with tivozanib 1.5 mg daily, 3 weeks on/1 week off in 28-day cycles. Brain MRI and blood biomarkers of angiogenesis were performed at baseline, within 24–72 h of treatment initiation, and monthly thereafter. Dynamic contrast enhanced MRI, dynamic susceptibility contrast MRI, and vessel architecture imaging were used to assess vascular effects. Resting state MRI was used to assess brain connectivity. Best RANO criteria responses were: 1 complete response, 1 partial response, 4 stable diseases, and 4 progressive disease (PD). Two patients were taken off study for toxicity and 8 patients were taken off study for PD. Median progression-free survival was 2.3 months and median overall survival was 8.1 months. Baseline abnormal tumor vascular permeability, blood flow, tissue oxygenation and plasma sVEGFR2 significantly decreased and plasma PlGF and VEGF increased after treatment, suggesting an anti-angiogenic effect of tivozanib. However, there were no clear structural changes in vasculature as vessel caliber and enhancing tumor volume did not significantly change. Despite functional changes in tumor vasculature, tivozanib had limited anti-tumor activity, highlighting the limitations of anti-VEGF monotherapy. Future studies in glioblastoma should leverage the anti-vascular activity of agents targeting VEGF to enhance the activity of other therapies.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalJournal of Neuro-Oncology
DOIs
StateAccepted/In press - Nov 16 2016
Externally publishedYes

Fingerprint

Glioblastoma
Vascular Endothelial Growth Factor A
Blood Vessels
Neoplasms
Vascular Endothelial Growth Factor Receptor
Brain
Capillary Permeability
Therapeutics
Tumor Burden
Protein-Tyrosine Kinases
Disease-Free Survival
Biomarkers
tivozanib
Survival

Keywords

  • Anti-angiogenesis
  • Glioblastoma
  • MRI
  • Overall survival
  • Progression-free survival
  • Tivozanib

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Kalpathy-Cramer, J., Chandra, V., da, X., Ou, Y., Emblem, K. E., Muzikansky, A., ... Gerstner, E. R. (Accepted/In press). Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. Journal of Neuro-Oncology, 1-8. https://doi.org/10.1007/s11060-016-2332-5

Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. / Kalpathy-Cramer, Jayashree; Chandra, Vyshak; da, Xiao; Ou, Yangming; Emblem, Kyrre E.; Muzikansky, Alona; Cai, Xuezhu; Douw, Linda; Evans, John G.; Dietrich, Jorg; Chi, Andrew S.; Wen, Patrick Y.; Stufflebeam, Stephen; Rosen, Bruce; Duda, Dan G.; Jain, Rakesh K.; Batchelor, Tracy T.; Gerstner, Elizabeth R.

In: Journal of Neuro-Oncology, 16.11.2016, p. 1-8.

Research output: Contribution to journalArticle

Kalpathy-Cramer, J, Chandra, V, da, X, Ou, Y, Emblem, KE, Muzikansky, A, Cai, X, Douw, L, Evans, JG, Dietrich, J, Chi, AS, Wen, PY, Stufflebeam, S, Rosen, B, Duda, DG, Jain, RK, Batchelor, TT & Gerstner, ER 2016, 'Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma', Journal of Neuro-Oncology, pp. 1-8. https://doi.org/10.1007/s11060-016-2332-5
Kalpathy-Cramer, Jayashree ; Chandra, Vyshak ; da, Xiao ; Ou, Yangming ; Emblem, Kyrre E. ; Muzikansky, Alona ; Cai, Xuezhu ; Douw, Linda ; Evans, John G. ; Dietrich, Jorg ; Chi, Andrew S. ; Wen, Patrick Y. ; Stufflebeam, Stephen ; Rosen, Bruce ; Duda, Dan G. ; Jain, Rakesh K. ; Batchelor, Tracy T. ; Gerstner, Elizabeth R. / Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. In: Journal of Neuro-Oncology. 2016 ; pp. 1-8.
@article{6227b2fa6482439bb5ee1f96841a0ab1,
title = "Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma",
abstract = "Targeting tumor angiogenesis is a potential therapeutic strategy for glioblastoma because of its high vascularization. Tivozanib is an oral pan-VEGF receptor tyrosine kinase inhibitor that hits a central pathway in glioblastoma angiogenesis. We conducted a phase II study to test the effectiveness of tivozanib in patients with recurrent glioblastoma. Ten adult patients were enrolled and treated with tivozanib 1.5 mg daily, 3 weeks on/1 week off in 28-day cycles. Brain MRI and blood biomarkers of angiogenesis were performed at baseline, within 24–72 h of treatment initiation, and monthly thereafter. Dynamic contrast enhanced MRI, dynamic susceptibility contrast MRI, and vessel architecture imaging were used to assess vascular effects. Resting state MRI was used to assess brain connectivity. Best RANO criteria responses were: 1 complete response, 1 partial response, 4 stable diseases, and 4 progressive disease (PD). Two patients were taken off study for toxicity and 8 patients were taken off study for PD. Median progression-free survival was 2.3 months and median overall survival was 8.1 months. Baseline abnormal tumor vascular permeability, blood flow, tissue oxygenation and plasma sVEGFR2 significantly decreased and plasma PlGF and VEGF increased after treatment, suggesting an anti-angiogenic effect of tivozanib. However, there were no clear structural changes in vasculature as vessel caliber and enhancing tumor volume did not significantly change. Despite functional changes in tumor vasculature, tivozanib had limited anti-tumor activity, highlighting the limitations of anti-VEGF monotherapy. Future studies in glioblastoma should leverage the anti-vascular activity of agents targeting VEGF to enhance the activity of other therapies.",
keywords = "Anti-angiogenesis, Glioblastoma, MRI, Overall survival, Progression-free survival, Tivozanib",
author = "Jayashree Kalpathy-Cramer and Vyshak Chandra and Xiao da and Yangming Ou and Emblem, {Kyrre E.} and Alona Muzikansky and Xuezhu Cai and Linda Douw and Evans, {John G.} and Jorg Dietrich and Chi, {Andrew S.} and Wen, {Patrick Y.} and Stephen Stufflebeam and Bruce Rosen and Duda, {Dan G.} and Jain, {Rakesh K.} and Batchelor, {Tracy T.} and Gerstner, {Elizabeth R.}",
year = "2016",
month = "11",
day = "16",
doi = "10.1007/s11060-016-2332-5",
language = "English (US)",
pages = "1--8",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma

AU - Kalpathy-Cramer, Jayashree

AU - Chandra, Vyshak

AU - da, Xiao

AU - Ou, Yangming

AU - Emblem, Kyrre E.

AU - Muzikansky, Alona

AU - Cai, Xuezhu

AU - Douw, Linda

AU - Evans, John G.

AU - Dietrich, Jorg

AU - Chi, Andrew S.

AU - Wen, Patrick Y.

AU - Stufflebeam, Stephen

AU - Rosen, Bruce

AU - Duda, Dan G.

AU - Jain, Rakesh K.

AU - Batchelor, Tracy T.

AU - Gerstner, Elizabeth R.

PY - 2016/11/16

Y1 - 2016/11/16

N2 - Targeting tumor angiogenesis is a potential therapeutic strategy for glioblastoma because of its high vascularization. Tivozanib is an oral pan-VEGF receptor tyrosine kinase inhibitor that hits a central pathway in glioblastoma angiogenesis. We conducted a phase II study to test the effectiveness of tivozanib in patients with recurrent glioblastoma. Ten adult patients were enrolled and treated with tivozanib 1.5 mg daily, 3 weeks on/1 week off in 28-day cycles. Brain MRI and blood biomarkers of angiogenesis were performed at baseline, within 24–72 h of treatment initiation, and monthly thereafter. Dynamic contrast enhanced MRI, dynamic susceptibility contrast MRI, and vessel architecture imaging were used to assess vascular effects. Resting state MRI was used to assess brain connectivity. Best RANO criteria responses were: 1 complete response, 1 partial response, 4 stable diseases, and 4 progressive disease (PD). Two patients were taken off study for toxicity and 8 patients were taken off study for PD. Median progression-free survival was 2.3 months and median overall survival was 8.1 months. Baseline abnormal tumor vascular permeability, blood flow, tissue oxygenation and plasma sVEGFR2 significantly decreased and plasma PlGF and VEGF increased after treatment, suggesting an anti-angiogenic effect of tivozanib. However, there were no clear structural changes in vasculature as vessel caliber and enhancing tumor volume did not significantly change. Despite functional changes in tumor vasculature, tivozanib had limited anti-tumor activity, highlighting the limitations of anti-VEGF monotherapy. Future studies in glioblastoma should leverage the anti-vascular activity of agents targeting VEGF to enhance the activity of other therapies.

AB - Targeting tumor angiogenesis is a potential therapeutic strategy for glioblastoma because of its high vascularization. Tivozanib is an oral pan-VEGF receptor tyrosine kinase inhibitor that hits a central pathway in glioblastoma angiogenesis. We conducted a phase II study to test the effectiveness of tivozanib in patients with recurrent glioblastoma. Ten adult patients were enrolled and treated with tivozanib 1.5 mg daily, 3 weeks on/1 week off in 28-day cycles. Brain MRI and blood biomarkers of angiogenesis were performed at baseline, within 24–72 h of treatment initiation, and monthly thereafter. Dynamic contrast enhanced MRI, dynamic susceptibility contrast MRI, and vessel architecture imaging were used to assess vascular effects. Resting state MRI was used to assess brain connectivity. Best RANO criteria responses were: 1 complete response, 1 partial response, 4 stable diseases, and 4 progressive disease (PD). Two patients were taken off study for toxicity and 8 patients were taken off study for PD. Median progression-free survival was 2.3 months and median overall survival was 8.1 months. Baseline abnormal tumor vascular permeability, blood flow, tissue oxygenation and plasma sVEGFR2 significantly decreased and plasma PlGF and VEGF increased after treatment, suggesting an anti-angiogenic effect of tivozanib. However, there were no clear structural changes in vasculature as vessel caliber and enhancing tumor volume did not significantly change. Despite functional changes in tumor vasculature, tivozanib had limited anti-tumor activity, highlighting the limitations of anti-VEGF monotherapy. Future studies in glioblastoma should leverage the anti-vascular activity of agents targeting VEGF to enhance the activity of other therapies.

KW - Anti-angiogenesis

KW - Glioblastoma

KW - MRI

KW - Overall survival

KW - Progression-free survival

KW - Tivozanib

UR - http://www.scopus.com/inward/record.url?scp=84995414662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995414662&partnerID=8YFLogxK

U2 - 10.1007/s11060-016-2332-5

DO - 10.1007/s11060-016-2332-5

M3 - Article

SP - 1

EP - 8

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

ER -